[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

However, given the recent failure of Sanofi's oral SERD amcenestrant in the phase 2 AMEERA-3 trial – which included a similar patient population – the new result is a worrying readout for the ...

The decision to abandon development of the oral selective oestrogen receptor degrader (SERD) comes after an ... patients who have discontinues aromatase inhibitor therapy due to toxicity.

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with ...

AstraZeneca has a few phase III trials underway, including the SERENA-6 trial which will pit camizestrant and cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors against aromatase inhibitors (a form of ...